GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Scaled Net Operating Assets

Mabpharm (HKSE:02181) Scaled Net Operating Assets : 0.32 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Mabpharm's operating assets for the quarter that ended in Dec. 2023 was HK$942.43 Mil. Mabpharm's operating liabilities for the quarter that ended in Dec. 2023 was HK$623.28 Mil. Mabpharm's Total Assets for the quarter that ended in Jun. 2023 was HK$987.63 Mil. Therefore, Mabpharm's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.32.


Mabpharm Scaled Net Operating Assets Historical Data

The historical data trend for Mabpharm's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Scaled Net Operating Assets Chart

Mabpharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial 0.81 0.33 0.50 0.49 0.31

Mabpharm Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.57 0.49 0.46 0.32

Competitive Comparison of Mabpharm's Scaled Net Operating Assets

For the Biotechnology subindustry, Mabpharm's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mabpharm's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabpharm's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Mabpharm's Scaled Net Operating Assets falls into.



Mabpharm Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Mabpharm's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(942.431-623.282)/1024.609
=0.31

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1132.032 - 189.601
=942.431

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=907.745 - 147.458 - 137.005
=623.282

Mabpharm's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Jun. 2023 )
=(942.431-623.282)/987.628
=0.32

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1132.032 - 189.601
=942.431

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=907.745 - 147.458 - 137.005
=623.282

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mabpharm Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Mabpharm's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Mabpharm (HKSE:02181) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).
Executives
Guo Jianjun 2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines